Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges

for the ISTAART Blood Based Biomarker Professional Interest Area

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms. Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70). Discussion: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume3
DOIs
StatePublished - 2016

Fingerprint

Malus
Alzheimer Disease
Biomarkers
Fatty Acid-Binding Proteins
Interleukin-18
Serum Amyloid A Protein
Pancreatic Polypeptide
beta 2-Microglobulin
Factor VII
Tumor Necrosis Factor Receptors
Interleukin-5
Serum
Interleukin-10
Proteomics
Interleukin-6
Proteins
Technology

Keywords

  • Alzheimer's disease
  • Biomarker discovery
  • Blood
  • Diagnostics
  • Meso Scale Discovery
  • Multiplex assay platform
  • Plasma
  • Preanalytic processing
  • Proteins
  • Rules Based Medicine
  • Serum
  • Standardization

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Comparing biological markers of Alzheimer's disease across blood fraction and platforms : Comparing apples to oranges. / for the ISTAART Blood Based Biomarker Professional Interest Area.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 3, 2016, p. 27-34.

Research output: Contribution to journalArticle

@article{799d0d58675d4cdda73e165434440f13,
title = "Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges",
abstract = "Introduction: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms. Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50{\%} of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50{\%} of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70). Discussion: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.",
keywords = "Alzheimer's disease, Biomarker discovery, Blood, Diagnostics, Meso Scale Discovery, Multiplex assay platform, Plasma, Preanalytic processing, Proteins, Rules Based Medicine, Serum, Standardization",
author = "{for the ISTAART Blood Based Biomarker Professional Interest Area} and O'Bryant, {Sid E.} and Simone Lista and Rissman, {Robert A.} and Melissa Edwards and Fan Zhang and James Hall and Henrik Zetterberg and Simon Lovestone and Veer Gupta and {Graff Radford}, {Neill R} and Ralph Martins and Andreas Jeromin and Stephen Waring and Esther Oh and Mitchel Kling and Baker, {Laura D.} and Harald Hampel",
year = "2016",
doi = "10.1016/j.dadm.2015.12.003",
language = "English (US)",
volume = "3",
pages = "27--34",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Comparing biological markers of Alzheimer's disease across blood fraction and platforms

T2 - Comparing apples to oranges

AU - for the ISTAART Blood Based Biomarker Professional Interest Area

AU - O'Bryant, Sid E.

AU - Lista, Simone

AU - Rissman, Robert A.

AU - Edwards, Melissa

AU - Zhang, Fan

AU - Hall, James

AU - Zetterberg, Henrik

AU - Lovestone, Simon

AU - Gupta, Veer

AU - Graff Radford, Neill R

AU - Martins, Ralph

AU - Jeromin, Andreas

AU - Waring, Stephen

AU - Oh, Esther

AU - Kling, Mitchel

AU - Baker, Laura D.

AU - Hampel, Harald

PY - 2016

Y1 - 2016

N2 - Introduction: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms. Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70). Discussion: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.

AB - Introduction: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms. Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70). Discussion: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.

KW - Alzheimer's disease

KW - Biomarker discovery

KW - Blood

KW - Diagnostics

KW - Meso Scale Discovery

KW - Multiplex assay platform

KW - Plasma

KW - Preanalytic processing

KW - Proteins

KW - Rules Based Medicine

KW - Serum

KW - Standardization

UR - http://www.scopus.com/inward/record.url?scp=84959378033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959378033&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.12.003

DO - 10.1016/j.dadm.2015.12.003

M3 - Article

AN - SCOPUS:84959378033

VL - 3

SP - 27

EP - 34

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -